STOCKHOLM (Reuters) -Denmark’s Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European Medicines Agency for approval, with one in three trial participants achieving 25% or more weight loss.
Novo Nordisk said in a statement it aimed to make the higher dose available throughout the European Union.
“This marks another significant milestone in the company’s goal to provide a broad portfolio of innovative and person-centric solutions to support people living with obesity,” it said.
(Reporting by Anna Ringstrom. Editing by Essi Lehto and Mark Potter)
